Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Total Non-Current Liabilities (2023)

Immunome's Total Non-Current Liabilities history spans 1 years, with the latest figure at $27.3 million for Q4 2023.

  • For Q4 2023, Total Non-Current Liabilities changed N/A year-over-year to $27.3 million; the TTM value through Dec 2023 reached $27.3 million, changed N/A, while the annual FY2023 figure was $27.3 million, N/A changed from the prior year.
  • Total Non-Current Liabilities reached $27.3 million in Q4 2023 per IMNM's latest filing, down from $87.0 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $87.0 million in Q3 2023 to a low of $27.3 million in Q4 2023.